Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study

Autor: Steendam, Christi M.J., Ernst, Sophie M., Badrising, Sushil K., Paats, Marthe S., Aerts, Joachim G.J.V., de Langen, Adrianus J., Dingemans, Anne-Marie C.

Publikováno v: In Lung Cancer July 2023 181

Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

Autor: Smesseim, Illaa, van der Wel, Tijmen, Badrising, Sushil K.

Publikováno v: In JTO Clinical and Research Reports December 2024 5(12)

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

Autor: Badrising, Sushil K., Louhanepessy, Rebecca D., van der Noort, Vincent, Kieffer, Jacobien, Coenen, Jules L. L. M., Hamberg, Paul, Beeker, Aart, Wagenaar, Nils, Lam, Marnix, Celik, Filiz, Loosveld, Olaf J. L., Oostdijk, Ad, Zuetenhorst, Hanneke, de Feijter, Jeantine M., Dezentjé, Vincent O., Ras-van Spijk, Suzan, Vegt, Erik, Haanen, John B., van de Poll-Franse, Lonneke V., Zwart, Wilbert, Bergman, Andries M.

Publikováno v: Prostate Cancer and Prostatic Diseases; February 2022, Vol. 25 Issue: 2 p248-255, 8p

Prognostic Parameters for Response to Enzalutamide After Docetaxel and Abiraterone Treatment in Metastatic Castration-Resistant Prostate Cancer Patients; a Possible Time Relation

Autor: Badrising, Sushil K., van der Noort, Vincent, van den Eertwegh, Alfons J. M., Hamberg, Paul, van Oort, Inge M., van den Berg, Hendrik P., Los, Maartje, Aarts, Maureen J. B., Coenen, Jules L. L. M., Gelderblom, Hans, de Jong, Igle J., Kerver, Emile D., Vrijaldenhoven, Suzan, van Voorthuizen, Theo, Warmerdam, Fabienne, Haanen, John B., Bergman, Andries M.

Publikováno v: Prostate, 76(1), 32-40. Wiley-Blackwell
Badrising, S K, van der Noort, V, van den Eertwegh, A J M, Hamberg, P, van Oort, I M, van den Berg, H P, Los, M, Aarts, M J B, Coenen, J L L M, Gelderblom, H, de Jong, I J, Kerver, E D, Vrijaldenhoven, S, van Voorthuizen, T, Warmerdam, F, Haanen, J B, Bergman, A M & Dutch Uro-Oncology Studygroup 2016, ' Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation ', Prostate, vol. 76, no. 1, pp. 32-40 . https://doi.org/10.1002/pros.23094
Prostate, 76(1), 32-40. Wiley-Liss Inc.
Prostate, 76(1), 32-40. Wiley

BACKGROUND. Abiraterone Acetate (AA) and Enzalutamide (Enz) are effective hormonal treatments in mCRPC patients. Retrospective studies suggested clinical cross-resistance between Enz and AA. However, 12.8-39.1% of patients previously treated with doc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ac1e784ea3542d94681e6d87a2a89589
https://research.rug.nl/en/publications/2ea11c24-1eaa-447e-b60f-1d6069233754